QSAR of cytochrome inhibitors

Expert Opinion on Drug Metabolism and Toxicology

Volumn 5, Issue 10, 2009, Pages 1245-1266

  Roy, Kunal ^a   Roy, Partha Pratim ^a  

^a JADAVPUR UNIVERSITY   (India)

Author keywords

ADMET; Cytochrome; Metabolism; QSAR

Indexed keywords

ALDOSTERONE SYNTHASE; AMIODARONE; CIPROFLOXACIN; CITALOPRAM; CYTOCHROME P450 1A2; CYTOCHROME P450 2A6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C8; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; DISULFIRAM; DRUG METABOLIZING ENZYME; ENOXACIN; ERYTHROMYCIN; FLUOXETINE; ISONIAZID; KETOCONAZOLE; METHOXSALEN; METRONIDAZOLE; MOCLOBEMIDE; OFLOXACIN; PAROXETINE; PILOCARPINE; SERTRALINE; SULFAMETHOXAZOLE; TRANYLCYPROMINE; UNINDEXED DRUG;

BIOASSAY; COMPUTER PREDICTION; CONCENTRATION RESPONSE; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG SAFETY; DRUG STRUCTURE; ENZYME INHIBITION; HORMONE METABOLISM; HUMAN; LIVER MICROSOME; METABOLIC REGULATION; NONHUMAN; PHARMACOGENETICS; PROTEIN EXPRESSION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REVIEW; TOXICOKINETICS;

ANIMALS; COMPUTATIONAL BIOLOGY; CYTOCHROME P-450 ENZYME SYSTEM; DRUG DESIGN; DRUG INTERACTIONS; ENZYME INHIBITORS; HUMANS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; XENOBIOTICS;

EID: 70349386376     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425250903158940     Document Type: Review

References (231)

1. Waterbeemd HV, Gifford E. ADMET in silico modeling: towards prediction paradise? Nat Rev Drug Discov 2003;2:192-204
2. Butina D, Segall MD, Frankcombe K. Predicting ADME properties, in silico: methods and models. Drug Discov Today 2002;7(11):S83-8 (Pubitemid 34603635)
3. Tollman P. A revolution in R&D. How genomics and genetic are transforming the biopharmaceutical industry. The Boston Consulting Group, 2001
4. Rogers AE. Benchmarking chemistry functions within pharmaceutical drug discovery and preclinical development. Drug Discov World 2002:67-71
5. Dimasi JA. Risks in new drug development: approval success rates for investigational drugs. Clin Pharmacol Ther 2001;69:297-307
6. Kennedy T. Managing the drug discovery/development interface. Drug Discov Today 1997;2:436-444
7. Yu H, Adedoyin A. ADME-Tox in drug discovery: integration of experimental and computational technologies. Drug Discov Today 2003;8(18):852-861 (Pubitemid 37083343)
8. FDA: Innovation stagnation: challenge and opportunity on the critical path to new medicinal products, 2004
9. Gibson GG, Skett P. Introduction to drug metabolism. Nelson Thorns, Cheltenham, 2001
10. Lewis DFV, Dickins M. Substrate SARs in human P450s. Drug Discov Today 2002;7(17):928-935
11. Lipinski CA. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 1997;23:3-25
12. Ekins S, De Groot M, Jones JP .Pharmacophore and three dimensional quantitative structure activity relationship methods for modeling cytochrome P450 active sites. Drug Metab Dispos 2001;29:936-944 (Pubitemid 32605906)
13. Ekins S, Berbaum J, Harrison RK. Generation and validation of rapid computational filters for CYP2D6 and CYP3A4. Drug Metab Dispos 2003;31:1077-1080 (Pubitemid 37048276)
14. Crivori P, Poggesi I. Computational approaches for predicting CYP-related metabolism properties in the screening of new drugs. Eur J Med Chem 2006;41:795-808
15. Bertrand M, Jackson P, Walther P. Rapid assessment of drug metabolism in the drug discovery process. Eur J Pharm Sci 2000;11(2 Suppl):S61-72 (Pubitemid 30734418)
16. Pelkonen O, Turpeinen M, Hakkola J, et al. Inhibition and induction of human cytochrome P450 enzymes: current status. Arch Toxicol 2008;82:667-715
17. Wienkers LC, Heath TG. Predicting in vivo drug interactions from in vitro drug discovery data. Nat Rev Drug Discov 2005;4:825-833
18. Guengerich FP. Cytochrome p450 and chemical toxicology. Chem Res Toxicol 2008;21:70-83
19. Omura T, Sato R. The carbon monoxide-binding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 1964;239:2370-2378
20. Arimoto R. Computational models for predicting interactions with cytochrome p450 enzyme. Curr Top Med Chem 2006;6(6):1609-1618 (Pubitemid 44313416)
21. Sellers EM, Kaplan HL. Inhibition of cytochrome P450 2A6 increases nicotine's oral bioavailability and decreases smoking. Clin Pharmacol Ther 2000;68:35
22. Sellers EM, Ramamoorthy Y, Zeman MV. The effect of methoxsalen on nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) metabolism invivo. Nicotine Tob Res 2003;5:891-899 (Pubitemid 38029085)
23. Patten CJ, Smith TJ, Friesen MJ, et al. Evidence for cytochrome P450 2A6 and 3A4 as major catalysts for N'-nitrosonornicotine alpha-hydroxylation by human liver microsomes. Carcinogenesis 1997;18:1623-1630
24. Fujita K, Kamataki T. Predicting the mutagenicity of tobacco-related N-nitrosamines in humans using 11 strains of Salmonella typhimurium YG7108, each coexpressing a form of human cytochrome P450 along with NADPH-cytochrome P450 reductase. Environ Mol Mutagen 2001;38:339 (Pubitemid 34052170)
25. Available from: http://drnelson.utmen.edu/CytochromeP450.html
26. Hodgson E. Invitro phase1 metabolism of xenobiotics 1: pesticides and related chemicals used in agriculture and public health. J Biochem Mol Toxicol 2001;15:296-299 (Pubitemid 33123264)
27. Rendic S, Dicarlo FJ. Human cytochrome P450 enzymes: a status report summarizing their reactions, substrate, inducers and inhibitors. Drug Metab Rev 1997;29:413-580 (Pubitemid 27293618)
28. Lewis DFV, Lake BG. Molecular modelling of CYP4A subfamily members based on sequence homology with CYP102. Xenobiotica 1999;29:763-781
29. Anzenbacher P, Anzenbacherova E. Cytochromes P450 and metabolism of xenobiotics. Cell Mol Life Sci 2001;58:737-747
30. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491
31. Ingelman-Sundberg M. Implications of polymorphic cytochrome P450-dependent drug metabolism for drug development. Drug Metab Dispos 2001;29:570-573 (Pubitemid 32275538)
32. Yamashita F, Hashida M. In silico approaches for predicting ADME properties of drugs. Drug Metab Pharmacokinet 2004;19:327-338
33. Williams PA, Cosme J, Sridhar V, et al. Microsomal cytochrome P450 2C5: comparison to microbial P450s and unique features. J Inorg Biochem 2000;81:183-190 (Pubitemid 30686219)
34. Williams PA, Cosme J, Ward A, et al. Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 2003;424:464-468 (Pubitemid 36917499)
35. Wester MR, Yano JK, Schoch GA, et al. The structure of human microsomal cytochrome P450 2C9 complexed with flurbiprofen at 2.0 A resolution. J Biol Chem 2004;279:35630-35637 (Pubitemid 39100565)
36. Williams PA, Cosme J, Vinkovic DM, et al. Crystal structures of human cytochrome P450 3A4 bound to metyrapone and progesterone. Science 2004;305:683-686 (Pubitemid 39006760)
37. Yano JK, Wester MR, Schoch GA, et al. The structure of human microsomal cytochrome P450 3A4 determined by X-ray crystallography to 2.05 A resolution. J Biol Chem 2004;279:38091-38094
38. Schoch GA, Yano JK, Wester MR, et al. Structure of human microsomal cytochrome P450 2C8: evidence for a peripheral fatty acid binding site. J Biol Chem 2004;279:9497-9503
39. De Groot MJ, Ekins S. Pharmacophore modeling of cytochromes P450. Adv Drug Deliv Rev 2002;54:367-383
40. Ekins S, De Groot MJ, Jones JP. Pharmacophore and three- threedimensional quantitative structure activity relationship methods for dimensional modeling cytochrome p450 active sites. Drug Metab Dispos 2001;29:936-944 (Pubitemid 32605906)
41. De Graaf C, Vermeulen NP, Feenstra KA. Cytochrome p450 insilico: an integrative modeling approach. J Med Chem 2005;48:2725-2755 (Pubitemid 40548088)
42. Jalaie M, Arimoto R, Gifford E, et al. Prediction of drug-like molecular properties: modeling cytochrome p450 interactions. Methods Mol Biol 2004;275:449-520
43. Guengerich FP. Human Cytochrome P450 enzymes. In: Ortriz de Montellano RP, editor, Cytochrome P450 structure, Mechanism and Biochemistry, Kluwer Acadennic, Plenum, New York, USA, 2004
44. Ding X, Kaminsky LS. Human extrahepatic cytochromes P450: function in xenobiotic metabolism and tissue-selective chemical toxicity in the respiratory and gastrointestinal tracts. Annu Rev Pharmacol Toxicol 2003;43:149-173 (Pubitemid 37372638)
45. Yano JK, Hsu MH, Griffin KJ, et al. Structures of human microsomal cytochrome P450 2A6 complexed with coumarin and methoxsalen. Nat Struct Mol Biol 2005;12:822-823
46. Lewis DFV, Lake BG, George SG, et al. Molecular modelling of CYP1 family enzymes CYP1A1, CYP1A2, CYP1A6 and CYP1B1 based on sequence homology with CYP102. Toxicology 1999;139:53-79
47. Sansen S, Yano JK, Reynald LR, et al. Adaptations for the oxidation of polycyclic aromatic hydrocarbons exhibited by the structure of human P450 1A2. J Bio Chem 2007;282:14348-14355 (Pubitemid 47100434)
48. Guengerich FP, Shimada T. Oxidation of toxic and carcinogenic chemicals by human cytochrome P-450 enzymes. Chem Res Toxicol 1991;4:391-407
49. Segura J, Roberts DJ, Tarrùs E. The influence of structure on the accumulation of caffeine induced by methyl xanthine derivatives. J Pharm Pharmacol 1988;41:129-131 (Pubitemid 19109547)
50. Fuhr V, Strobl G, Manaut F, et al. Quinolone antibacterial agents: Relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993;43:191-199 (Pubitemid 23055062)
51. Sanz F, Lopez-De-Brinas E, Rodriques J, Manaut F. Theoretical study on the metabolism of caffeine by cytochrome P-450 1A2 and its inhibition. Quant Struct Act Relat 1994;13:281-284 (Pubitemid 24319343)
52. Lee H, Yeom H, Kim YG, et al. Structure-related inhibition of human hepatic caffeine N3-demethylation by naturally occurring flavonoids. Biochem Pharmacol 1998;55:1369-1375 (Pubitemid 28298516)
53. De Rienzo F, Fanelli F, Menziani MC, De Benedetti PG. Theoretical investigation of substrate specificity for cytochromes P450 IA2, P450 IID6 and P450 IIIA4. J Comput Aided Mol Des 2000;14:93-116 (Pubitemid 30103825)
54. Lozano JJ, Pastor M, Cruciani G, et al. 3D-QSAR methods on the basis of ligand receptor complexes. Application of COMBINE and GRID/GOLPE methodologies to a series of CYP1A2 ligands. J Comput Aided Mol Des 2000;14:341-353 (Pubitemid 30219396)
55. Lewis DFV. On the recognition of mammalian microsomal cytochrome P450 substrates and their characteristics. Biochem Pharmacol 2000;60:293-306
56. Moon T, Chi MH, Kim D, et al. Quantitative structure-activity relationship (QSAR) study of flavonoid derivatives for inhibition of cytochrome P450 1A2. Quant Struct Act Relat 2000;19:257-263 (Pubitemid 30428231)
57. Kamataki T, Maeda K, Yamazoe Y, et al. A high-spin form of cytochrome P-450 highly purified from polychlorinated biphenyl-treated rats. Catalytic characterization and immunochemical quantitation in liver microsomes. Mol Pharmacol 1983;24:146-155
58. Butler MA, Iwasaki M, Guengerich FP, Kadlubar FF. Human cytochrome P450PA (P450IA2), the phenacetin O-deethylase, is primarily responsible for the hepatic 3-demethylation of caffeine and N-oxidation of carcinogenic arylamines. Proc Natl Acad Sci USA 1989;86:7696-7700 (Pubitemid 19265255)
59. Aoyama T, Gelboin HV, Gonzalez FJ. Mutagenic activation of 2-amino-3-methylimidazo[4,5-f]quinoline by complementary DNA expressed human liver P-450. Cancer Res 1990;50:2060-2063
60. Yanagawa Y, Sawada M, Deguchi T, et al. Stable expression of human CYP1A2 and N-acetyl transferase in Chinese hamster CHL cells: mutagenic activation of 2-amino-3- methylimidazo[4,5-f]quinoline and 2-amino-3,8-dimethylimidazo[4,5- f]quinoxaline. Cancer Res 1994;54:3422-3427
61. Arinc E, Sen A, Bozcaarmutlu A. Cytochrome P4501A and associated mixed function oxidase induction in fish as biomarker for toxic carcinogenic pollutants the aquatic environment. Pure Appl Chem 2000;72:985-994
62. Kleiner HE, Reed MJ, Digiovanni J. Naturally occurring coumarins inhibit human cytochromes P450 and block benzo[a]pyrene and 7,12-dimethylbenz[a] anthracene DNAadduct formation in MCF-7 cells. Chem Res Toxicol 2003;16:415-422
63. Shimada T, Yamazaki H, Guengerich FP. Ethnic-related differences in coumarin 7-hydroxylation activities catalyzed by cytochrome P4502A6 in liver microsomes of Japanese and Caucasian populations. Xenobiotica 1996;26:395-403 (Pubitemid 26150089)
64. Tredger JM, Stoll S. Cytochromes p450-their impact on drug treatment. Hosp Pharm 2002;9:167-173 (Pubitemid 34742511)
65. Rodriguez-Antona C, Ingelman-Sundberg M. Cytochrome P450 pharmacogenetics and cancer. Cytochrome P450 pharmacogenetics and cancer. Oncogene 2006;25:1679-1691
66. Miles JS, Mclaren AW, Forrester LM, et al. Identification of the human liver cytochrome P-450 responsible for coumarin 7-hydroxylase activity. Biochem J 1990;267:365-371
67. Yamano S, Tatsuno J, Gonzalez FJ. The CYP2A3 gene product catalyzes coumarin 7-hydroxylation in human liver microsomes. Biochemistry 1990;29:1322-1329 (Pubitemid 20053858)
68. Yun CH, Shimada T, Guengerich FP. Purification and characterization of human liver microsomal cytochrome P-450 2A6. Mol Pharmacol 1991;40:679-685
69. Oscarson M. Genetic polymorphisms in the cytochrome P450 2A6 (CYP2A6) gene: implications for interindividual differences in nicotine metabolism. Drug Metab Dispos 2001;29:91-95 (Pubitemid 32112920)
70. Available from: http://www.patentstorm.us/patents/7148046.html
71. Pelkonen O, Raunio H, Rautio A, et al. Coumarin 7-hydroxylase: characteristics and regulation in mouse and man. J Irsh Coll Phys Surg 1993;22:24 (Pubitemid 23176754)
72. Poulos TL, Finzel BC, Gunsalus IC, et al. The 2.6-A crystal structure of Pseudomonas putida cytochrome P-450. J Biol Chem 1985;260(30):16122-16130
73. Hukkanen J, Jacob P III, Benowitz NL. Metabolism and disposition kinetics of nicotine. Pharmacol Rev 2005;57:79-115
74. Lee AM, Tyndale RF. Drugs and genotypes: how pharmacogenetic information could improve smoking cessation treatment. J Psychopharmacol 2006;20:7-14
75. Ho MK, Tyndale RF. Overview of the pharmacogenomics of cigarette smoking. Pharmacogenomics J 2007;7:81-98
76. Agùndez JAG. Cytochrome P450 gene polymorphism and cancer. Curr Drug Metab 2004;5:211-224 (Pubitemid 38735776)
77. Nebert DW, Dalton TP. The role of cytochrome P450 enzymes in endogenous signalling pathways and environmental carcinogenesis. Nat Rev Cancer 2006;6:947-960
78. Mcfadyen MCE, Melvin WT, Murray GI. Regional distribution of individual forms of cytochrome P450 mRNA in normal adult human brain. Biochem Pharmacol 1998;55:825-830
79. Fromm MF, Kroemer HK, Eichelbaumm M. Impact of P450 genetic polymorphism on the first-pass extraction of cardiovascular and neuroactive drugs. Adv Drug Deliv Rev 1997;27:171-199
80. Flores A, Gastèlum EM, Bosseno MF, et al. Isoenzyme variability of five principal triatomine vector species of Chagas disease in Mexico. Infect Genet Evol 2001;1:21-28 (Pubitemid 33587020)
81. Frist WH, Groves JR, Merrill WH, et al. Physiological exercise response in heart transplant recipients at 1year. Transplant Proc 1992;24:2672-2673
82. Ingelman-Sundberg M. Genetic polymorphisms of cytochrome P450 2D6 (CYP2D6): clinical consequences, evolutionary aspects and functional diversity. Pharmacogenomics J 2005;5:6-13 (Pubitemid 40220611)
83. Zanger UM, Raimundo S, Eichelbaum M. Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn Schmiedebergs Arch Pharmacol 2004;369:23-37 (Pubitemid 38161221)
84. Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A. Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br J Clin Pharmacol 2002;53:111-122 (Pubitemid 34264265)
85. Hishiki T, Shimada H, Nagano S, et al. X-ray crystal structure and catalytic properties of Thr252Ile mutant of cytochrome P450cam: roles of Thr252 and water in the active center. J Biochem (Tokyo) 2000;128:965-974 (Pubitemid 32011567)
86. Wolff T, Distlerath LM, Worthington MT, et al. Substrate specificity of human liver cytochromeP-450 debrisoquine 4-hydroxylase probed using immunochemical inhibition and chemical modeling. Cancer Res 1985;45:2116-2122 (Pubitemid 15024394)
87. Meyer UA, Gut J, Kronbach T, et al. The molecular mechanisms of two common polymorphisms of drug oxidation-evidence for functional changes in cytochrome P-450 isozymes catalysing bufuralol and mephenytoin oxidation. Xenobiotica 1986;16:449-464 (Pubitemid 16076723)
88. Guengerich FP, Miller GP, Hanna IH, et al. Diversity in the oxidation of substrates by cytochrome P450 2D6: lack of an obligatory role of aspartate 301-substrate electrostatic bonding. Biochemistry 2002;41:11025-11034
89. Evans WE, Relling MV. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999;286:487-491
90. Smith DA, Jones BC. Speculations on the substrate structure-activity relationship (SSAR) of cytochrome P450 enzymes. Biochem Pharmacol 1992;44:2089-2098
91. Mancy A, Broto P, Dijols S, etal. The substrate binding site of human liver cytochrome P450 2C9: an approach using designed tienilic acid derivatives and molecular modeling. Biochemistry 1995;34:10365-10375
92. Transon T, Leemann T, Vogt N, Dayer P. Invivo inhibition profile of cytochrome P450TB (CYP2C9) by (+/-)-fluvastatin. Clin Pharmacol Ther 1995;58:412-417
93. Poli-Scaife S, Attias R, Dansette PM, Mansuy D. The substrate binding site of human liver cytochrome P450 2C9: an NMR study. Biochemistry 1997;36:12672-12682 (Pubitemid 27465377)
94. Hamman MA, Thompson GA, Hall SD. Regioselective and stereoselective metabolism of ibuprofen by human cytochrome P450 2C. Biochem Pharmacol 1997;54:33-41 (Pubitemid 27353220)
95. Miners JO, Coulter S, Tukey RH, et al. Cytochromes P450, 1A2, and 2C9 are responsible for the human hepatic O-demethylation of R- and S-naproxen. Biochem Pharmacol 1996;51:1003-1008 (Pubitemid 126333965)
96. Tracy TS, Marra C, Wrighton SA, et al. Studies of flurbiprofen 4'-hydroxylation. Additional evidence suggesting the sole involvement of cytochrome P450 2C9. Biochem Pharmacol 1996;52:1305-1309
97. Rettie AE, Korzekwa KR, Kunze KL, et al. Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 1992;5:54-59
98. Thijssen HH, Flinois JP, Beaune PH. Ytochrome P4502C9 is the principal catalyst of racemic acenocoumarol hydroxylation reactions in human liver microsomes. Drug Metab Dispos 2000;28:1284-1290
99. Yamazaki H, Shimada T. Progesterone and testosterone hydroxylation by cytochromes P450 2C19, 2C9, and 3A4 in human liver microsomes. Arch Biochem Biophys 1997;346:161-169 (Pubitemid 27415307)
100. Chang GW, Kam PC. The physiological and pharmacological role of CYP450 isoenzymes. Anasthesia 1999;54:42-50
101. Lewis DFV. 57 Varieties: the human cytochromes P450. Pharmacogenomics 2004;5:305-318
102. Bertilsson L. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995;29:192-209
103. Ingelman-Sundberg M, Sim SC, Gomez A. Influence of cytochrome P450 polymorphisms on drug therapies: pharmacogenetic, pharmacoepigenetic and clinical aspects. Pharmacol Ther 2007;116:496-526 (Pubitemid 350116943)
104. Li H, Sun J, Fan X, etal. Considerations and recent advances in QSAR models for cytochrome P450-mediated drug metabolism prediction. J Comput Aided Mol Des 2008;22:843-855
105. Yoo JS, Guengerich FP, Yang CS. Metabolism of N-nitrosodialkylamines by human liver microsomes. Cancer Res 1988;48:1499-1504 (Pubitemid 18091196)
106. Crespi CL, Penman BW, Leakey JA, et al. Human cytochrome P450IIA3: cDNA sequence, role of the enzyme in the metabolic activation of promutagens, comparison to nitrosamine activation by human cytochrome P450IIE1. Carcinogenesis 1990;11:1293-1300 (Pubitemid 20245700)
107. Yamazaki H, Oda Y, Funae Y, et al. Participation of rat liver cytochrome P450 2E1 in the activation of N-nitrosodimethylamine and N-nitrosodiethylamine to products genotoxic in an acetyltransferase-overexpressing Salmonella typhimurium strain (NM2009). Carcinogenesis 1992;13:979-985
108. Yamazaki H, Inui Y, Yun CH, et al. Cytochrome P450 2E1 and 2A6 enzymes as major catalysts for metabolic activation of N-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 1992;13:1789-1794
109. Koop DR, Coon MJ. Ethanol oxidation and toxicity: role of alcohol P-450 oxygenase. Alcohol Clin Exp Res 1986;10:44-49
110. Johansson I, Ingelman-Sundberg M. Benzene metabolism by ethanol-, acetone-, and benzene-inducible cytochrome P-450 (IIE1) in rat and rabbit liver microsomes. Cancer Res 1988;48:5387-5390 (Pubitemid 18242577)
111. Guengerich FP, Kim DH, Iwasaki M. Role of human cytochrome P-450 IIE1 in the oxidation of many low molecular weight cancer suspects. Chem Res Toxicol 1991;4:168-179
112. Perrot N, Nalpas B, Yang CS, Beaune PH. Modulation of cytochrome P450 isozymes in human liver, by ethanol and drug intake. Eur J Clin Invest 1989;19:549-555 (Pubitemid 20026998)
113. O'Shea D, Davis SN, Kim RB, Wilkinson GR. Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 1994;56:359-367 (Pubitemid 24339082)
114. Wang Z, Hall SD, Maya JF, etal. Diabetes mellitus increases the invivo activity of cytochrome P450 2E1 in humans. Br J Clin Pharmacol 2003;55:77-85 (Pubitemid 36110842)
115. Lewis DFV, Bird MG, Parke DV. Molecular modelling of CYP2El enzymes from rat, mouse and man: an explanation for species differences in butadiene metabolism and potential carcinogenicity, and rationalization of CYP2E substrate specificity. Toxicology 1997;118:93-113
116. Kessova I, Cederbaum AI. CYP2E1: biochemistry, toxicology, regulation and function in ethanol-induced liver injury. Curr Mol Med 2003;3:509-518 (Pubitemid 37168595)
117. Lieber CS. The discovery of the microsomal ethanol oxidizing system and its physiologic and pathologic role. Drug Metab Rev 2004;36:511-529
118. Shimada T, Yamazaki H, Mimura M, et al. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 1994;270:414-423 (Pubitemid 24229655)
119. Mimura M, Baba T, Yamazaki H, et al. Characterization of cytochrome P450 2B6 in human liver microsomes. Drug Metab Dispos 1993;21:1048-1056 (Pubitemid 23348341)
120. Heyn H, White RB, Stevens JC. Catalytic role of cytochrome P450 2B6 in the N-demethylation of S-mephenytoin. Drug Metab Dispos 1996;24:948-954 (Pubitemid 26314545)
121. Williams PA, Cosme J, Sridhar V, et al. Mammalian microsomal cytochrome P450 monooxygenase: structural adaptations for membrane binding and functional diversity. Mol Cell 2000;5:121-131 (Pubitemid 30105441)
122. Chang TK, Weber GF, Crespi CL, Waxman DJ. Differential activation of cyclophosphamide and ifosphamide by cytochromes P-450 2B and 3A in human liver microsomes. Cancer Res 1993;53:5629-5637
123. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of bupropion hydroxylation as a selective marker of human cytochrome P450 2B6 catalytic activity. Drug Metab Dispos 2000;28:1222-1230
124. Turpeinen M, Raunio H, Pelkonen O. The functional role of CYP2B6 in human drug metabolism: substrates and inhibitors invitro, invivo and insilico. Curr. Drug Metab 2006;7:705-714 (Pubitemid 44509677)
125. Kumagai J, Fujimura T, Takahashi S, et al. Cytochrome P450 2B6 is a growth-inhibitory and prognostic factor for prostate cancer. Prostate 2007;67:1029-1037 (Pubitemid 46983333)
126. Totah RA, Rettie AE. Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther 2005;77:341-352 (Pubitemid 40719263)
127. Rowland-Yeo K, Rostami-Hodjegan A, Tucker GT. Abundance of cytochromes P450 in human liver: a meta-analysis. Br J Clin Pharmacol 2003;57:687-688
128. Enayetallah AE, French RA, Thibodeau MS, Grant DF. Distribution of soluble epoxide hydrolase and of cytochrome P450 2C8, 2C9, and 2J2 in human tissues. J Histochem Cytochem 2004;52:447-454
129. Läpple F, Von Richter O, Fromm MF, et al. Differential expression and function of CYP2C isoforms in human intestine and liver. Pharmacogenetics 2003;13:565-575 (Pubitemid 37168057)
130. Li XQ, Björkman A, Andersson TB, et al. Amodiaquine clearance and its metabolism to N-desethylamodiaquine is mediated by CYP2C8: a new high affinity and turnover enzyme-specific probe substrate. J Pharmacol Exp Ther 2002;300:399-407 (Pubitemid 34106229)
131. Wen X, Wang JS, Backman JT, et al. Trimethoprim and sulfamethoxazole are selective inhibitors of CYP2C8 and CYP2C9, respectively. Drug Metab Dispos 2002;30:631-635 (Pubitemid 34579094)
132. Rahman A, Korzekwa KR, Grogan J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8. Cancer Res 1994;54:5543-5546 (Pubitemid 24980099)
133. Kajosaari LI, Jaakkola T, Neuvonen PJ, Backman JT. Pioglitazone, an invitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide. Eur J Clin Pharmacol 2006a;62:217-223 (Pubitemid 43357580)
134. Bidstrup TB, Bjornsdottir I, Sidelmann UG, et al. CYP2C8 and CYP3A4 are the principal enzymes involved in the human invitro biotransformation of the insulin secretagogue repaglinide. Br J Clin Pharmacol 2003;56:305-314 (Pubitemid 37059658)
135. Niemi M, Backman JT, Kajosaari LI, et al. Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin Pharmacol Ther 2005b;77:468-478 (Pubitemid 40824960)
136. Baldwin SJ, Clarke SE, Chenery RJ. Characterization of the cytochrome P450 enzymes involved in the invitro metabolism of rosiglitazone. Br J Clin Pharmacol 1999;48:424-432 (Pubitemid 29417728)
137. Rifkind AB, Lee C, Chang TK, Waxman DJ. Arachidonic acid metabolism by human cytochrome P450s 2C8, 2C9, 2E1, and 1A2: regioselective oxygenation and evidence for a role for CYP2C enzymes in arachidonic acid epoxygenation in human liver microsomes. Arch Biochem Biophys 1995;320:380-389
138. Nadin L, Murray M. Participation of CYP2C8 in retinoic acid 4-hydroxylation in human hepatic microsomes. Biochem Pharmacol 1999;58:1201-1208 (Pubitemid 29381521)
139. Zhang QY, Dunbar D, Ostrowska A, et al. Characterization of human small intestinal cytochromes P-450. Drug Metab Dispos 1999;27:804-809 (Pubitemid 29297778)
140. Scott EE, Halpert JR. Structures of cytochrome P450 3A4. Trends Biochem Sci 2005;30(1):5-7
141. Silvers KJ, Chazinski T, Mcmanus ME, et al. Cytochrome P-450 3A4 (nifedipine oxidase) is responsible for the C-oxidative metabolism of 1-nitropyrene in human liver microsomal samples. Cancer Res 1992;52(22):6237- 6243
142. Singh BS, Shen QL, Walker JM, Sheridan PR. A model for predicting likely sites of CYP3A4-mediated metabolism on drug-like molecules. J Med Chem 2003;46:1330-1336 (Pubitemid 36512698)
143. Domanski TL, He YA, Khan KK, et al. Phenylalanine and tryptophan scanning mutagenesis of CYP3A4 substrate recognition site residues and effect on substrate oxidation and cooperativity. Biochemistry 2001;40(34):10150-10160
144. Rendic S. Summary of information on human CYP enzymes: human P450 metabolism data. Drug Metabol Rev 2002;34(1-2):83-448 (Pubitemid 34311090)
145. Guengerich FP. Cytochrome P-450 3A4: regulation and role in drug metabolism. Annu Rev Pharmacol Toxicol 1999;39:1-7
146. Ahmad S, Wolf ES. Cisapride and torsades de pointes. Lancet 1995;345:508
147. Boxenbaum H. Cytochrome P450 3A4 in vivo ketoconazole competitive inhibition: determination of Ki and dangers associated with high clearance drugs in general. J Pharm Sci 1999;2:47-52
148. Lin JH, Lu AY. Inhibition and induction of cytochrome P450 and the clinical implications. Clin Pharmacokinet 1998;35:361-390 (Pubitemid 28520008)
149. Lewis DFV, Lake BG. Molecular modelling and quantitative structure-activity relationship studies on the interaction of omeprazole with cytochrome P450 isozymes. Toxicology 1998;125:31-44
150. Thompson EA, Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974;249:5364-5372
151. Simpson ER, etal. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 1994;15:342-355
152. O'Neal J. Aromatase inhibitors. Crit Rev Biochem Mol Biol 1998;33:375-405
153. Brueggemeier RW, Hackett JC, Diaz-Cruz ES. Aromatase inhibitors in the treatment of breast cancer. Endocr Rev 2005;26:331-345 (Pubitemid 40686647)
154. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009;457(7226):219-223
155. Kawamoto T, Mitsuuchi Y, Toda K, et al. Role of steroid 11beta-hydroxylase and steroid 18-hydroxylase in the biosynthesis of glucocorticoids and mineralocorticoids in humans. Proc Natl Acad Sci USA 1992;89:1458-1462
156. Saarikoskia TS, Riverac PS, Hankinsonc O, Husgafvel-Pursiainen K. CYP2S1: a short review. Toxicol Appl Pharmacol 2005;207:S62-9
157. Selassie CD. History of quantitative structure-activity relationships. In: Abraham DJ, editor, Burger's Medicinal Chemistry and Drug Discovery. John Wiley, New York, USA: 2003
158. Hansch C, Fujita T. Epsilon-sigma-pi analysis. A method for the correlation of biological activity and chemical structure. J Am Chem Soc 1964;86:1616-1626
159. Tong W, Hong H, Xie Q, etal. Assessing QSAR limitations - a regulatory perspective. Curr Comput Aided Drug Des 2005;1(2):195-205
160. Dearden JC. Insilico prediction of drug toxicity. J Comput Aided Mol Des 2003;17:119-127
161. Thibuat U. 3D-QSAR in drug design: theory, methods and applications. In: Kubinyi H, editor, ESCOM Science, Leiden, 1993
162. Leach AR, Gillet VJ. An introduction to chemoinformatics. Springer: Dordrecht, 2007
163. Kirkpatrick P. Gliding to success. Nat Rev Drug Discov 2004;3:299
164. He L, Jurs PC. Assessing the reliability of a QSAR model's predictions. J Mol Graph Model 2005;23(6):503-523 (Pubitemid 40803520)
165. Ghafourian T, Cronin MTD. The impact of variable selection on the modelling of oestrogenicity. SAR QSAR Environ Res 2005;16(1-2):171-190
166. Tropsha A, Gramatica P, Gombar VK. The importance of being earnest: validation is the absolute essential for successful application and interpretation of QSPR models. QSAR Comb Sci 2003;22(1):69-77 (Pubitemid 36717473)
167. Golbraikh A, Tropsha A. Beware of q2!. J Mol Graph Model 2002;20(4):269-276
168. Aptula AO, Jeliazkova NG, Schultz TW, Cronin MTD. The better predictive model: high q2 for the training set or low root mean square error of prediction for the test set?. QSAR Comb Sci 2005;24(3):385-396
169. Leonard JT, Roy K. On selection of training and test sets for the development of predictive QSAR models. QSAR Comb Sci 2006;25(3):235-251 (Pubitemid 350213175)
170. Roy PP, Roy K. On some aspects of variable selection for partial least squares regression models. QSAR Comb Sci 2008;27(3):302-313
171. Roy K. On some aspects of validation of predictive quantitative structure-activity relationship models. Expert Opin Drug Discov 2007;2(12):1567-1577 (Pubitemid 350285346)
172. Roy K, Roy PP. Comparative QSAR studies of CYP1A2 inhibitor flavonoids using 2D and 3D descriptors. Chem Biol drug Des 2008;72:370-382
173. Wold S, Eriksson L. Statistical validation of QSAR results. In: van deWaterbeemd H, editor, Chemometrics Methods in Molecular Design. VCH, 1995
174. Fuhr U, Strobl G, Manaut F, et al. Quinolone antibacterial agents: relationship between structure and in vitro inhibition of the human cytochrome P450 isoform CYP1A2. Mol Pharmacol 1993;43:191-199 (Pubitemid 23055062)
175. Lewis DFV. Structural characteristics of human P450s involved in drug metabolism: QSARs and lipophilicity profiles. Toxicology 2000;144:197-203
176. Lewis DFV. Quantitative structure-activity relationships (QSARs) within the cytochrome P450 system: QSARs describing substrate binding, inhibition and
177. Iori F, Fonseca Da R, Ramos BJM, Menziania MC. Theoretical quantitative structure-activity relationships of flavone ligands interacting with cytochrome P450 1A1 and 1A2 isozymes. Bioorg Med Chem 2005;13:4366-4374 (Pubitemid 40813224)
178. Jung J, Kim ND, Kim SY, et al. Regioselectivity prediction of CYP1A2-mediated phase i metabolism. J Chem Inf Model 2008;48:1074-1080
179. Korhonen LE, Rahnasto M, Mahonen NJ, et al. Predictive three-dimensional quantitative structure-activity relationship of cytochrome P450 1A2 inhibitors. J Med Chem 2005;48:3808-3815 (Pubitemid 40776855)
180. Chohan KK, Paine SW, Mistry J, et al. A rapid computational filter for cytochrome P450 1A2 inhibition potential of compound libraries. J Med Chem 2005;48:5154-5161 (Pubitemid 41113903)
181. Vasanthanathan P, Taboureau O, Oostenbrink C, etal. Classification of cytochrome P450 1A2 inhibitors and noninhibitors by machine learning techniques. Drug Metab Dispos 2009;37(3):658-664
182. Li JK, He F, Bi HC, etal. Inhibition of human cytochrome P-450 CYP1A2 by flavonoids: a quantitative structure-activity relationship study. Yao Xue Xue Bao 2008;43(12):1198-1204
183. Ekins S, Bravi G, Wikel J, Wrighton AS. Three-dimensional-quantitative structure activity relationship analysis of cytochrome P-450 3A4 substrates. J Pharmacol Exp Ther 1999;291:424-433 (Pubitemid 29451619)
184. Ekins S, Bravi G, Binkley S, et al. Three- and four-dimensional quantitative structure activity relationship analyses of cytochrome P-450 3A4 inhibitors. J Pharmacol Exp Ther 1999;290:429-438 (Pubitemid 29302353)
185. Wanchana S, Yamashita F, Hashida M. QSAR analysis of the inhibition of recombinant CYP 3A4 activity by structurally diverse compounds using a genetic algorithm-combined partial least squares method. Pharm Res 2003;20:1401-1408 (Pubitemid 37164048)
186. Riley RJ, Parker AJ, Trigg S, Manners CN. Development of a generalized,quantitative physicochemical model of CYP3A4 inhibition for use in early drug discovery. Pharm Res 2001;18(5):652-655 (Pubitemid 32595794)
187. Kriegl JM, Eriksson L, Arnhold T, et al. Multivariate modeling of cytochrome P450 3A4 inhibition. Eur J Pharm Sci 2005;24:451-463 (Pubitemid 40387259)
188. Kriegl JM, Arnhold T, Beck B, Fox T. A support vector machine approach to classify human cytochrome P450 3A4 inhibitors. J Comput Aided Mol Des 2005;19:189-201 (Pubitemid 40974006)
189. Mao B, Gozalbes R, Barbosa F, et al. QSAR Modeling of inVitro inhibition of cytochrome P450 3A4. J Chem Inf Model 2006;46:2125-2134 (Pubitemid 44625983)
190. Row EC, Brown SA, Stachulskib AV, Lennarda MS. Synthesis of 8-geranyloxypsoralen analogues and their evaluation as inhibitors of CYP3A4. Bioorg Med Chem 2006;14:3865-3871
191. Itokawa D, Nishioka T, Fukushima J, et al. Quantitative structure activity relationship study of binding affinity of azole compounds with CYP2B and CYP3A. QSAR Comb Sci 2007;26:828-836 (Pubitemid 47121259)
192. Roy K, Roy PP. Exploring QSARs for binding affinity of azoles with CYP2B and CYP3A enzymes using GFA and G/PLS techniques. Chem Biol Drug Des 2008;71:464-71
193. Roy K, Roy PP. Comparative chemometric modeling of cytochrome 3A4 inhibitory activity of structurally diverse compounds using stepwise MLR, FA-MLR, PLS, GFA, G/PLS and ANN techniques. Eur J Med Chem 2009;44:2913-2922
194. Molnar L, Keseru GM. A neural network based virtual screening of cytochrome P450 3A4 inhibitors. Bioorg Med Chem Lett 2002;12:419-421 (Pubitemid 34113917)
195. Zuegge J, Fechnera U, Roche O, et al. A fast virtual screening filter for cytochrome P450 3A4 inhibition liability of compound libraries. Quant Struct Act Relat 2002;21:249-256 (Pubitemid 34951595)
196. Kemp CA, Flanagan JU, Van Eldik AJ, et al. Validation of model of cytochrome P450 2D6: an insilico tool for predicting metabolism and inhibition. J Med Chem 2004;47:5340-5346
197. Susnow GR, Dixon LS. Use of robust classification techniques for the prediction of human cytochrome P450 2D6 inhibition. J Chem Inf Comput Sci 2003;43:1308-1315
198. Burton J, Ijjaali I, Barberan O, et al. Recursive partitioning for the prediction of cytochromes P450 2D6 and 1A2 inhibition: importance of the quality of the dataset. J Med Chem 2006;49:6231-6240 (Pubitemid 44595200)
199. Bazeley SP, Prithivi S, Struble AC, et al. Synergistic use of compound properties and docking scores in neural network modeling of CYP2D6 binding: predicting affinity and conformational sampling. J Chem Inf Model 2006;46:2698-2708 (Pubitemid 46008139)
200. Sciabola S, Morao I, De Groot MJ. Pharmacophoric fingerprint method (TOPP) for 3D-QSAR modeling: application to CYP2D6 metabolic stability. J Chem Inf Model 2007;47:76-84 (Pubitemid 46225562)
201. Jensen FB, Vind C, Padkjaeœr BS, et al. Insilico prediction of cytochrome P450 2D6 and 3A4 inhibition using gaussian kernel weighted k-nearest neighbor and extended connectivity fingerprints, including structural fragment analysis of inhibitors versus noninhibitors. J Med Chem 2007;50:501-511 (Pubitemid 46239784)
202. Ai C, Li Y, Wang Y, etal. Insight into the effects of chiral isomers quinidine and quinine on CYP2D6 inhibition. Bioorg Med Chem Lett 2009;19(3):803-806
203. Vaz RJ, Nayeem A, Santone K, et al. A 3D-QSAR model for CYP2D6 inhibition in the aryloxypropanolamine series. Bioorg Med Chem Lett 2005;15:3816-3820 (Pubitemid 41095475)
204. Ito Y, Kondo H, Goldfarb PS, Lewis DFV. Analysis of CYP2D6 substrate interactions by computational methods. J Mol Graph Model 2008;26:947-956 (Pubitemid 350298014)
205. Roy PP, Roy K. QSAR studies of CYP2D6 inhibitor aryloxypropanolamine using 2D and 3D descriptors. Chem Biol Drug Des 2009;73:442-455
206. O'Brien SE, de Groot MJ. Greater than the sum of its parts: combining models for useful ADMET prediction. J Med Chem 2005;48:1287-1291
207. Poso A, Gynther J, Juvonen RA. Comparative molecular field analysis of cytochrome P450 2A5 and 2A6 inhibitors. J Comput Aided Mol Des 2001;15:195-202 (Pubitemid 32219934)
208. Asikainen A, Tarhanen J, Poso A, et al. Predictive value of comparative molecular field analysis modelling of naphthalene inhibition of human CYP2A6 and mouse CYP2A5 enzymes. Toxicol InVitro 2003;17:449-455 (Pubitemid 36776786)
209. Rahnasto M, Raunio H, Poso A, et al. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Med Chem 2005;48:440-449 (Pubitemid 40139786)
210. Asikainen AH, Ruuskanen J, Tuppurainen KA. Alternative QSAR models for selected estradiol and cytochrome P450 ligands: comparison between classical, spectroscopic, CoMFA and GRID/GOLPE methods. SAR QSAR Environ Res 2005;16(6):555-565 (Pubitemid 43163264)
211. Rahnasto M, Wittekindt C, Juvonen RO, et al. Identification of inhibitors of the nicotine metabolising CYP2A6 enzyme-an in silico approach. Pharmacogenomics J 2008;8(5):328-338
212. Van Damme S, Bultinck P. Conceptual DFT properties-based 3D QSAR: Analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme. J Comput Chem 2009;30:1749-1757
213. Roy K, Roy PP. Exploring QSAR and QAAR for inhibitors of cytochrome P450 2A6 and 2A5 enzymes using GFA and G/PLS techniques. Eur J Med Chem 2009;44:1941-1951
214. Leong MK, Chen YM, Chen HB, Chen PH. Development of a new predictive model for interactions with human cytochrome P450 2A6 using Pharmacophore Ensemble/Support Vector Machine (PhE/SVM) approach. Pharm Res 2009;26(4):987-1000
215. Jones JP, He M, Trager WF, Rettie AE. Three-dimensional quantitative structure-activity relationship for inhibitors of cytochrome P4502C9. Drug Metab Dispos 1996;24:1-6 (Pubitemid 26029580)
216. Haining RL, Jones JP, Henne KR, et al. Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the pi-stacking anchor site for warfarin binding. Biochemistry 1999;38:3285-3292 (Pubitemid 29148903)
217. Rao S, Aoyama R, Schrag M, et al. A refined 3-dimensional QSAR of cytochrome P450 2C9: computational predictions of drug interactions. J Med Chem 2000;43:2789-2796 (Pubitemid 30599636)
218. Locuson CW, Wahlstrom JL. Three-dimensional quantitative structure-activity relationship analysis of cytochromes p450: effect of incorporating higher-affinity ligands and potential new applications. Drug Metab Dispos 2005;33(7):873-878
219. Afzelius L, Masimirembwa CM, Karlen A, et al. Discriminant and quantitative PLS analysis of competitive CYP2C9 inhibitors versus non-inhibitors using alignment independent GRIND descriptors. J Comput Aided Mol Des 2002;16:443-458 (Pubitemid 36018696)
220. Afzelius L, Zamora I, Ridderstrom M, et al. Competitive CYP2C9 inhibitors: enzyme inhibition studies, protein homology modeling, and three-dimensional quantitative structure-activity relationship analysis. Mol Pharmacol 2001;59:909-919 (Pubitemid 32274021)
221. Afzelius L, Zamora I, Masimirembwa CM, etal. Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. J Med Chem 2004;47:907-914 (Pubitemid 38176793)
222. Peng CC, Rushmore T, Croucha GJ, Jonesa JP. Modeling and synthesis of novel tight-binding inhibitors of cytochrome P450 2C9. Bioorg Med Chem 2008;16:4064-4074
223. Gleeson MP, Davis AM, Chohan KK, et al. Generation of in-silico cytochrome P450 1A2, 2C9, 2C19, 2D6, and 3A4 inhibition QSAR models. J Comput Aided Mol Des 2007;21:559-573
224. Byvatov E, Baringhaus KH, Schneider G, Matter H. A virtual screening filter for identification of cytochrome P450 2C9 (CYP2C9) inhibitors. QSAR and Comb Sci 2007;26:618-628 (Pubitemid 46932851)
225. Lewis DFV, Lake BG, Ito Y, Dickins M. Lipophilicity relationships in inhibitors of CYP2C9 and CYP2C19 enzymes. J Enzyme Inhib Med Chem 2006;21(4):385-389 (Pubitemid 44355787)
226. Locuson CW 2nd, Suzuki H, Rettie AE, Jones JP. Charge and substituent effects on affinity and metabolism of benzbromarone-based CYP2C19 inhibitors. J Med Chem 2004;47(27):6768-6776
227. Korhonen LE, Turpeinen M, Rahnasto M, et al. New potent and selective cytochrome P450 2B6 (CYP2B6) inhibitors based on three-dimensional quantitative structure-activity relationship (3D-QSAR) analysis. Br J Pharmacol 2007;150:932-942 (Pubitemid 46536632)
228. Leonetti F, Favia A, Rao A, et al. Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem 2004;47(27):6792- 6803 (Pubitemid 40053767)
229. Nagar S, Islam MDA, Das S, et al. Pharmacophore mapping of flavone derivatives for aromatase inhibition. Mol Divers 2008;12:65-76
230. Castellano S, Stefancich G, Ragno R, et al. CYP19 (aromatase): exploring the scaffold flexibility novel selective inhibitors. Bioorg Med Chem 2008;16:8349-8358
231. De Groot MJ. Designing better drugs: predicting Cytochrome p450 metabolism. Drug Discov Today 2006;11(13-14):601-606